A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2018
Price : $35 *
At a glance
- Drugs Botulism vaccine (Primary)
- Indications Botulism
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 30 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Nov 2018 Planned End Date changed from 1 Sep 2023 to 1 Sep 2019.
- 30 Nov 2018 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2019.